Sue Dillon, Karyn O'Neil steer fledgling Aro Biotherapeutics to $13M debut — with J&J's blessing
When news first broke that R&D heavyweights Sue Dillon and Karyn O’Neil left J&J to launch Aro Biotherapeutics, precious little was known about the company …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.